Compare United States Copper Index Fund (CPER) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Novartis AG — how do they compare? United States Copper Index Fund trades at $40.24 (market cap $708.28M), while Novartis AG trades at $142.98 (market cap $268.57B). The key difference: Novartis AG is far larger — about 379.2× United States Copper Index Fund's market cap, and Novartis AG pays a 3.31% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Novartis AG for 82 Days on average.
| CPER | NVS | |
|---|---|---|
Market Cap | $708.28M | $268.57B |
Volume | 339,046 | 1,532,573 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $168.62 |
52-Week Low | $30.27 | $121.80 |
Typical Hold Time | 48 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish momentum in moving averages but neutral oscillators, with key support at $39 and resistance at $40. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper prices have shown volatility with recent declines.
The outlook for CPER is mixed, with positive copper demand fundamentals balanced by near-term price volatility. Investment opportunities center on exposure to copper's role in AI and electrification trends, while risks include commodity price swings and potential supply chain disruptions. Wall Street sentiment appears cautiously optimistic given copper's strategic importance.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
